The Patent Finder

Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms

Interpace Diagnostics Corporation

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 61/414,778, filed Nov 17, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,150,999Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
In force
 · High confidence
Interpace Diagnostics, LLCIn force
High confidence
US 11,118,231Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
In force
 · High confidence
Interpace Diagnostics, LLCIn force
High confidence
Application 17/400,660Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
Abandoned
Abandoned Sep 27, 2024
Interpace Diagnostics, LLCAbandonedAbandoned Sep 27, 2024
Application 18/815,470Mirnas as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
Pending
Not granted
Interpace Diagnostics, LLCPendingNot granted
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Interpace Diagnostics Corporation.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited